Accelr8's Q3 Revenues Drop Sharply
June 13, 2012
Accelr8's Q3 Revenues Drop Sharply
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Accelr8 Extends Agreement for Evaluation of BACcel System
June 30, 2011 / GenomeWeb Daily News - Genoptix Joins Growing List of Companies Licensing TrovaGene's NPM1 for AML Testing
January 2, 2013 / Pharmacogenomics Reporter - Novartis' Genoptix Licenses Trovagene Marker for AML Services
December 20, 2012 / GenomeWeb Daily News - FDA Approves Pfizer's Chronic Philadelphia Chromosome-Positive CML Drug Bosulif
September 5, 2012 / Pharmacogenomics Reporter - Novartis Research Group Aims to Use NGS, Other Technologies to Develop Personalized Cancer Dx
August 8, 2012 / Clinical Sequencing News